(Country; Symbol)

(Country; Symbol)

Change from original

Terms/Details (Date)

Cambridge Antibody Technology plc (UK; CATG; LSE:CAT)

Dyax Corp. (DYAX)

Expanded agreement widening the access and freedom to operate under each other's phage display patents

CAT is granting Dyax worldwide licenses for research and certain other purposes under its antibody phage display patents; CAT could receive milestone and royalty payments on antibody products; it also has an option to co-fund and co-develop antibodies discovered by Dyax (1/6)

Gene Logic Inc.

Genentech Inc. (NYSE:DNA)

Renewed subscription agreement for the BioExpress System

Genentech renewed its subscription for multiple years; the BioExpress dataset includes gene expression information derived from a range of normal and diseased human tissue, animal and cell lines and detailed associated clinical annotations (2/19)

Genentech Inc. (NYSE:DNA)

Serono SA (Switzerland; NYSE:SRA)

Expanded overseas development and marketing agreement to add 15 Asian countries to an existing deal that covered Europe

Serono has worldwide rights outside of the U.S., except in Japan, where Genentech has rights; Genentech and partner XOMA Ltd. have rights in the U.S. (2/6)

Inpharmatica Ltd.*
(UK) of protein families and genomic sequences

Serono SA (Switzerland; NYSE:SRA)

Expanded research collaboration to use Inpharmatica's PharmaCarta technology platform to deliver sequences

Inpharmatica will receive additional unspecified research funding and milestone and royalty payments based on development and sales of resulting products (1/28)

NicOx SA (France; Nouveau Marche:

Biolipox AB* (Sweden)

Expansion of a research and co-development agreement on a class of nitric oxide-donating therapeutics in the respiratory field

The collaboration combines NicOx's intellectual property and expertise in the nitric oxide field with Biolipox's expertise in the characterization of mechanisms and screening of compounds for the treatment of airway diseases in order to identify drug candidates (1/29)

Revotar Biopharmaceuticals
(Germany; majority-owned affiliate of Texas BiotechnologyCorp.; TXBI)

Texas Biotechnology Corp. (TXBI)

Amended license and research and development agreement in order to better reflect individual commercial priorities

Revotar will have exclusive worldwide rights to bimosiamose to treat asthma and other inflammatory conditions as well as rights to topical indications outside of North America; Texas Biotechnology will have exclusive worldwide rights to use bimosiamose in organ transplant as well as exclusive North American rights to all topical indications; each party retains certain revenue-sharing and royalty obligations (2/7)

Symyx Technologies Inc. (SMMX)

Celanese Chemicals* (unit of Celanese AG; Germany)

Extended research and development collaboration focusing on the discovery of breakthrough catalysts for the production of commodity chemicals

Celanese will continue to fund Symyx's discovery efforts, and will have exclusive rights to commercialize materials discovered within the field of the collaboration; Symyx would receive royalties on resulting products (1/29)


Antares Pharma Inc. (ANTR)

Bio-Technology General Corp.*

Terminated agreement for Antares' needle-free injector technology for use with human growth hormones in the U.S.

Antares reacquired the rights and is free to pursue distribution of the technology in the U.S. market with other partners (2/7)

Crucell NV (the Netherlands; CRXL)

Centocor Inc. (unit of Johnson & Johnson)

Terminated development of the anti-CD46 antibody to treat cancer

Crucell regains all rights to the target and antibody (12/26)

Cytogen Corp.

Northwest Biotherapeutics Inc. (OTC BB:NWBT)

Terminated agreement for ex vivo prostate cancer immunotherapy using prostate-specific membrane antigen

Northwest terminated the program for funding reasons; Cytogen will regain all rights (12/26)

Texas Biotechnology Corp. (TXBI)


Terminated agreement for development and worldwide marketing rights to sitaxsentan, a pulmonary arterial hypertension drug developed by ICOS-Texas Biotechnology LP, a partnership between the companies

Under the joint venture, all research, development and marketing costs were to be shared equally, as were profits on any product sales; financial terms of the latest transaction were not disclosed (1/31)


# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board